CClinicalTrials.gg
CompletedNCT06798389Updated Apr 24, 2025

CMSL Ambulatory Sensitive Condition Nudge

An interventional study of Nurse Nudge in Behavioral Intervention, Emergency Department Visits and Nurse Care Coordination, sponsored by Geisinger Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
3,016
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The project aims to evaluate a nurse-led intervention to reduce inappropriate emergency department (ED) use among adult patients seen at Geisinger's Community Medicine Service Line (CMSL) clinics. The intervention occurs immediately following an appointment where they received a diagnosis of an ambulatory sensitive condition (ASC). The evaluation will compare eligible patients with an ASC who were randomly assigned to receive follow-up outreach from a nurse (who was automatically prompted via the Epic electronic health record system to initiate outreach) with those who were randomly assigned to receive standard care. Analyses will be intent-to-treat. The primary outcome is ED use in the week following the appointment.

02

Conditions studied

  • Behavioral Intervention
  • Emergency Department Visits
  • Nurse Care Coordination

Browse trials for

Keywords

  • Nudge
03

In context

Emergencies

1,692 studies on the registry are indexed under Emergencies; 333 are open to participants now.

This study's enrollment of 3,016 is above the median of 145 across 931 interventional studies indexed under Emergencies.

Browse Emergencies studies →

Lead sponsor

Geisinger Clinic is the lead sponsor of 125 studies on the registry; 21 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age 18 years +
  • Has a visit in CMSL with an ambulatory sensitive condition (ASC) encounter diagnosis
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,016 participants (actual)

Study arms

  • Experimental
    Nurse Nudge

    Nurses in CMSL clinics will receive a notification to provide follow-up outreach to patients after the patient receives an ambulatory sensitive diagnosis.

    Behavioral: Nurse Nudge

  • No intervention
    Control

    Nurses in CMSL clinics will receive standard follow-up notifications, which may mean no notifications, after a patient has received an ambulatory sensitive diagnosis.

Interventions

  • BehavioralNurse Nudge

    Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post-appointment follow-up call.

06

What researchers measure

Primary outcomes

  1. ED Visit (yes/no)

    Does outreach decrease ED visits?

    Time frame: within 7 days following day of appointment

Other outcomes

  1. Nurse call to patient

    Does the nurse nudge increase post-appointment nurse calls to patients?

    Time frame: Within 7 days post-appointment

07

Study locations

1 site
  • Geisinger
    Danville, Pennsylvania 17821, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 24, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06798389
Lead sponsor
Geisinger Clinic
Responsible party
Amir Goren (Program Director, Geisinger Clinic) — Principal investigator
First posted
Jan 29, 2025
Start date
Jan 6, 2025
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Last update
Apr 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion